Miscellaneous immune disorders:
Indications for FIRDAPSE:
Lambert-Eaton myasthenic syndrome (LEMS).
Initially 15–30mg daily in 3–4 divided doses. May increase by 5mg every 3 or 4 days. Max 80mg/day. Max single dose: 20mg. Hepatic or renal impairment (CrCl 15–90mL/min), NAT2 poor metabolizers: 15mg daily in 3 divided doses.
History of seizures.
Consider dose reduction or discontinuation if seizure occurs. Discontinue and treat if anaphylaxis occurs. Hepatic or renal impairment: monitor; adjust dose or discontinue as needed. N-acetyltransferase 2 (NAT2) poor metabolizers. Elderly. Pregnancy. Nursing mothers.
Potassium channel blocker.
Concomitant drugs that lower seizure threshold may increase seizure risk. Additive effects when concomitant drugs with cholinergic effects (eg, direct or indirect cholinesterase inhibitors).
Paresthesia, upper RTI, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, muscle spasms; seizures, hypersensitivity.
Tabs—60, 240; Blister packs—10, 120